Get the Stockscreener App
478.16
1.42%
-6.90
After Hours:
478.16
United Therapeutics Corp stock is traded at $478.16, with a volume of 315.91K.
It is down -1.42% in the last 24 hours and down -1.48% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$485.06
Open:
$478.05
24h Volume:
315.91K
Relative Volume:
0.80
Market Cap:
$20.96B
Revenue:
$3.13B
Net Income/Loss:
$1.27B
P/E Ratio:
18.12
EPS:
26.3851
Net Cash Flow:
$1.12B
1W Performance:
-5.11%
1M Performance:
-1.48%
6M Performance:
+19.38%
1Y Performance:
+55.41%
1-Day Range:
$471.29
$484.73
1-Week Range:
$471.29
$527.14
52-Week Range:
$266.98
$537.19
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
478.16 | 21.26B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.88 | 56.11B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
121.43 | 51.60B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.28 | 46.00B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.05 | 36.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Ray Kurzweil Sells 4,910 Shares of United Therapeutics Corp - GuruFocus
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock - MarketBeat
United Therapeutics (UTHR) Receives Increased Price Target from UBS | UTHR Stock News - GuruFocus
UBS raises United Therapeutics stock price target to $705 on catalysts - Investing.com Canada
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate - ChartMill
AustralianSuper Pty Ltd Cuts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics pill shows late-stage success in rare lung disease PAH - IndiaMedToday
TD Cowen reiterates United Therapeutics stock Buy on ralinepag trial success - Investing.com India
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics CEO to give update at Leerink healthcare conference - Stock Titan
Leerink raises United Therapeutics stock price target on trial data By Investing.com - Investing.com South Africa
Jefferies raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
Jefferies raises United Therapeutics stock price target on trial data - Investing.com India
United Therapeutics Hits Day High with 13% Surge in Strong Intraday Performance - Markets Mojo
H.C. Wainwright reiterates Buy on United Therapeutics stock By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy on United Therapeutics stock - Investing.com
United Therapeutics (UTHR): Investor Outlook With A 13% Upside Potential - DirectorsTalk Interviews
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - marketscreener.com
United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening - Benzinga
United Therapeutics reports positive phase 3 trial for ralinepag By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Reports Positive Phase 3 Results for Ralinepag - GuruFocus
United Therapeutics reports positive phase 3 trial for ralinepag - Investing.com
United Therapeutics: Ralinepag cuts risk of clinical worsening by 55% in pivotal PAH trial - TradingView
Ralinepag cuts PAH clinical worsening by 55% in UTHR (NASDAQ: UTHR) phase 3 trial - Stock Titan
Once-daily PAH drug by United Therapeutics slows progressive disease - Stock Titan
United Therapeutics Corporation $UTHR Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600 - Finviz
United Therapeutics’ Stock Run Sets Up Big H1 2026 Trial Tests - Finimize
United Therapeutics Earnings Call Signals Growth Ahead - TipRanks
United Therapeutics Corp. Hits New 52-Week High at $537.11 - Markets Mojo
United Therapeutics Corporation (NASDAQ:UTHR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics Corp. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
H.C. Wainwright raises United Therapeutics stock price target to $600 - Investing.com Nigeria
United Therapeutics (NASDAQ:UTHR) Given New $600.00 Price Target at HC Wainwright - MarketBeat
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings - Benzinga
H.C. Wainwright raises United Therapeutics stock price target to $600 By Investing.com - Investing.com Australia
Why United Therapeutics (UTHR) Shares Are Sliding Today - Finviz
Oppenheimer Raises United Therapeutics (UTHR) Price Target to $6 - GuruFocus
Wells Fargo Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
UTHR: RBC Capital Raises Price Target for United Therapeutics | - GuruFocus
Wells Fargo & Company Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price - MarketBeat
UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance - Finviz
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2025 Earnings Call Transcript - Insider Monkey
MANNKIND CORP SEC 10-K Report - TradingView
United Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.55%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):